ID   SGPL1_HUMAN             Reviewed;         568 AA.
AC   O95470; B2RBD4; Q7Z732; Q9ULG8; Q9UN89;
DT   24-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   24-OCT-2003, sequence version 3.
DT   12-APR-2017, entry version 146.
DE   RecName: Full=Sphingosine-1-phosphate lyase 1 {ECO:0000305};
DE            Short=S1PL {ECO:0000305};
DE            Short=SP-lyase 1 {ECO:0000305};
DE            Short=SPL 1 {ECO:0000305};
DE            Short=hSPL;
DE            EC=4.1.2.27 {ECO:0000269|PubMed:11018465, ECO:0000269|PubMed:24809814};
DE   AltName: Full=Sphingosine-1-phosphate aldolase;
GN   Name=SGPL1 {ECO:0000312|HGNC:HGNC:10817};
GN   Synonyms=KIAA1252 {ECO:0000303|PubMed:10574462};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, PATHWAY, FUNCTION,
RP   MUTAGENESIS OF CYS-218 AND CYS-317, AND TISSUE SPECIFICITY.
RX   PubMed=11018465; DOI=10.1016/S1388-1981(00)00079-2;
RA   Van Veldhoven P.P., Gijsbers S., Mannaerts G.P., Vermeesch J.R.,
RA   Brys V.;
RT   "Human sphingosine-1-phosphate lyase: cDNA cloning, functional
RT   expression studies and mapping to chromosome 10q22.";
RL   Biochim. Biophys. Acta 1487:128-134(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND MUTAGENESIS OF LYS-353.
RX   PubMed=14570870; DOI=10.1074/jbc.M309646200;
RA   Reiss U., Oskouian B., Zhou J., Gupta V., Sooriyakumaran P., Kelly S.,
RA   Wang E., Merrill A.H. Jr., Saba J.D.;
RT   "Sphingosine-phosphate lyase enhances stress-induced ceramide
RT   generation and apoptosis.";
RL   J. Biol. Chem. 279:1281-1290(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NITRATION [LARGE SCALE ANALYSIS] AT TYR-356 AND TYR-366, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Pituitary adenoma;
RX   PubMed=16777052; DOI=10.1016/j.ab.2006.05.024;
RA   Zhan X., Desiderio D.M.;
RT   "Nitroproteins from a human pituitary adenoma tissue discovered with a
RT   nitrotyrosine affinity column and tandem mass spectrometry.";
RL   Anal. Biochem. 354:279-289(2006).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-564, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-353, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 62-568 IN COMPLEX WITH
RP   PYRIDOXAL PHOSPHATE AND SYNTHETIC INHIBITOR, CATALYTIC ACTIVITY,
RP   PATHWAY, FUNCTION, COFACTOR, SUBUNIT, AND BIOPHYSICOCHEMICAL
RP   PROPERTIES.
RX   PubMed=24809814; DOI=10.1021/jm500338n;
RA   Weiler S., Braendlin N., Beerli C., Bergsdorf C., Schubart A.,
RA   Srinivas H., Oberhauser B., Billich A.;
RT   "Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-
RT   methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of
RT   sphingosine 1-phosphate lyase for the treatment of multiple
RT   sclerosis.";
RL   J. Med. Chem. 57:5074-5084(2014).
CC   -!- FUNCTION: Cleaves phosphorylated sphingoid bases (PSBs), such as
CC       sphingosine-1-phosphate, into fatty aldehydes and
CC       phosphoethanolamine. Elevates stress-induced ceramide production
CC       and apoptosis. {ECO:0000269|PubMed:11018465,
CC       ECO:0000269|PubMed:14570870, ECO:0000269|PubMed:24809814}.
CC   -!- CATALYTIC ACTIVITY: Sphinganine 1-phosphate = phosphoethanolamine
CC       + palmitaldehyde. {ECO:0000269|PubMed:11018465,
CC       ECO:0000269|PubMed:24809814}.
CC   -!- COFACTOR:
CC       Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;
CC         Evidence={ECO:0000269|PubMed:24809814};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=5.2 uM for sphingosine 1-phosphate
CC         {ECO:0000269|PubMed:24809814};
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC       {ECO:0000269|PubMed:11018465, ECO:0000269|PubMed:24809814}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:24809814}.
CC   -!- INTERACTION:
CC       Q86WV6:TMEM173; NbExp=2; IntAct=EBI-1046170, EBI-2800345;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Single-pass
CC       type III membrane protein.
CC   -!- TISSUE SPECIFICITY: Found in liver and kidney.
CC       {ECO:0000269|PubMed:11018465}.
CC   -!- SIMILARITY: Belongs to the group II decarboxylase family.
CC       Sphingosine-1-phosphate lyase subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA86566.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ011304; CAA09590.2; -; mRNA.
DR   EMBL; AF144638; AAD44755.1; -; mRNA.
DR   EMBL; AB033078; BAA86566.1; ALT_INIT; mRNA.
DR   EMBL; AK314615; BAG37181.1; -; mRNA.
DR   EMBL; CH471083; EAW54414.1; -; Genomic_DNA.
DR   EMBL; BC052991; AAH52991.1; -; mRNA.
DR   CCDS; CCDS31216.1; -.
DR   RefSeq; NP_003892.2; NM_003901.3.
DR   RefSeq; XP_005270320.1; XM_005270263.1.
DR   RefSeq; XP_011538618.1; XM_011540316.2.
DR   RefSeq; XP_011538619.1; XM_011540317.1.
DR   UniGene; Hs.499984; -.
DR   PDB; 4Q6R; X-ray; 2.40 A; A/B=62-568.
DR   PDBsum; 4Q6R; -.
DR   ProteinModelPortal; O95470; -.
DR   SMR; O95470; -.
DR   BioGrid; 114398; 46.
DR   IntAct; O95470; 15.
DR   STRING; 9606.ENSP00000362298; -.
DR   BindingDB; O95470; -.
DR   ChEMBL; CHEMBL3286061; -.
DR   DrugBank; DB00114; Pyridoxal Phosphate.
DR   GuidetoPHARMACOLOGY; 2522; -.
DR   SwissLipids; SLP:000000107; -.
DR   iPTMnet; O95470; -.
DR   PhosphoSitePlus; O95470; -.
DR   SwissPalm; O95470; -.
DR   BioMuta; SGPL1; -.
DR   EPD; O95470; -.
DR   MaxQB; O95470; -.
DR   PaxDb; O95470; -.
DR   PeptideAtlas; O95470; -.
DR   PRIDE; O95470; -.
DR   Ensembl; ENST00000373202; ENSP00000362298; ENSG00000166224.
DR   GeneID; 8879; -.
DR   KEGG; hsa:8879; -.
DR   UCSC; uc001jrm.4; human.
DR   CTD; 8879; -.
DR   DisGeNET; 8879; -.
DR   GeneCards; SGPL1; -.
DR   HGNC; HGNC:10817; SGPL1.
DR   HPA; HPA021125; -.
DR   HPA; HPA023086; -.
DR   MIM; 603729; gene.
DR   neXtProt; NX_O95470; -.
DR   OpenTargets; ENSG00000166224; -.
DR   PharmGKB; PA35725; -.
DR   eggNOG; KOG1383; Eukaryota.
DR   eggNOG; COG0076; LUCA.
DR   GeneTree; ENSGT00390000000046; -.
DR   HOGENOM; HOG000190693; -.
DR   HOVERGEN; HBG056982; -.
DR   InParanoid; O95470; -.
DR   KO; K01634; -.
DR   OMA; ACTLFHG; -.
DR   OrthoDB; EOG091G040L; -.
DR   PhylomeDB; O95470; -.
DR   TreeFam; TF300777; -.
DR   BRENDA; 4.1.2.27; 2681.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis.
DR   UniPathway; UPA00222; -.
DR   ChiTaRS; SGPL1; human.
DR   GeneWiki; SGPL1; -.
DR   GenomeRNAi; 8879; -.
DR   PRO; PR:O95470; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000166224; -.
DR   CleanEx; HS_SGPL1; -.
DR   ExpressionAtlas; O95470; baseline and differential.
DR   Genevisible; O95470; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; NAS:UniProtKB.
DR   GO; GO:0016831; F:carboxy-lyase activity; IEA:InterPro.
DR   GO; GO:0030170; F:pyridoxal phosphate binding; IEA:InterPro.
DR   GO; GO:0008117; F:sphinganine-1-phosphate aldolase activity; IDA:UniProtKB.
DR   GO; GO:0008209; P:androgen metabolic process; IEA:Ensembl.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006672; P:ceramide metabolic process; IDA:UniProtKB.
DR   GO; GO:0008210; P:estrogen metabolic process; IEA:Ensembl.
DR   GO; GO:0060325; P:face morphogenesis; IEA:Ensembl.
DR   GO; GO:0006631; P:fatty acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0010761; P:fibroblast migration; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; IEA:Ensembl.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:0033327; P:Leydig cell differentiation; IEA:Ensembl.
DR   GO; GO:0001553; P:luteinization; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0048705; P:skeletal system morphogenesis; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0030148; P:sphingolipid biosynthetic process; TAS:Reactome.
DR   GO; GO:0030149; P:sphingolipid catabolic process; IDA:UniProtKB.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   Gene3D; 3.40.640.10; -; 1.
DR   Gene3D; 3.90.1150.10; -; 1.
DR   InterPro; IPR002129; PyrdxlP-dep_de-COase.
DR   InterPro; IPR015424; PyrdxlP-dep_Trfase.
DR   InterPro; IPR015421; PyrdxlP-dep_Trfase_major_sub1.
DR   InterPro; IPR015422; PyrdxlP-dep_Trfase_sub2.
DR   Pfam; PF00282; Pyridoxal_deC; 1.
DR   SUPFAM; SSF53383; SSF53383; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; Complete proteome;
KW   Endoplasmic reticulum; Lipid metabolism; Lyase; Membrane; Nitration;
KW   Phosphoprotein; Polymorphism; Pyridoxal phosphate; Reference proteome;
KW   Signal-anchor; Sphingolipid metabolism; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    568       Sphingosine-1-phosphate lyase 1.
FT                                /FTId=PRO_0000147012.
FT   TOPO_DOM      1     40       Lumenal. {ECO:0000255}.
FT   TRANSMEM     41     61       Helical; Signal-anchor for type III
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     62    568       Cytoplasmic. {ECO:0000255}.
FT   MOD_RES     353    353       N6-(pyridoxal phosphate)lysine;
FT                                alternate.
FT   MOD_RES     353    353       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     356    356       Nitrated tyrosine.
FT                                {ECO:0000244|PubMed:16777052}.
FT   MOD_RES     366    366       Nitrated tyrosine.
FT                                {ECO:0000244|PubMed:16777052}.
FT   MOD_RES     564    564       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   VARIANT      21     21       V -> L (in dbSNP:rs12770335).
FT                                /FTId=VAR_048875.
FT   MUTAGEN     218    218       C->G: Loss of activity.
FT                                {ECO:0000269|PubMed:11018465}.
FT   MUTAGEN     317    317       C->S: Almost no activity.
FT                                {ECO:0000269|PubMed:11018465}.
FT   MUTAGEN     353    353       K->L: Loss of activity.
FT                                {ECO:0000269|PubMed:14570870}.
FT   CONFLICT    404    404       C -> A (in Ref. 1; CAA09590).
FT                                {ECO:0000305}.
FT   HELIX       123    134       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       135    137       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       139    142       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      145    148       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       154    165       {ECO:0000244|PDB:4Q6R}.
FT   TURN        166    169       {ECO:0000244|PDB:4Q6R}.
FT   TURN        175    177       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       179    195       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      203    209       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       210    227       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      234    238       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       244    252       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      255    259       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      265    267       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       269    273       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      280    286       {ECO:0000244|PDB:4Q6R}.
FT   TURN        290    292       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       298    308       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      312    316       {ECO:0000244|PDB:4Q6R}.
FT   TURN        317    319       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       320    323       {ECO:0000244|PDB:4Q6R}.
FT   TURN        324    330       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      344    349       {ECO:0000244|PDB:4Q6R}.
FT   TURN        351    355       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      362    368       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       369    372       {ECO:0000244|PDB:4Q6R}.
FT   TURN        373    375       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      377    381       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      387    392       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       398    434       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      448    454       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      456    458       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       461    469       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      475    477       {ECO:0000244|PDB:4Q6R}.
FT   TURN        478    481       {ECO:0000244|PDB:4Q6R}.
FT   STRAND      482    486       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       489    494       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       497    513       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       521    531       {ECO:0000244|PDB:4Q6R}.
FT   HELIX       535    549       {ECO:0000244|PDB:4Q6R}.
SQ   SEQUENCE   568 AA;  63524 MW;  3B16FDEFC4B2FDB6 CRC64;
     MPSTDLLMLK AFEPYLEILE VYSTKAKNYV NGHCTKYEPW QLIAWSVVWT LLIVWGYEFV
     FQPESLWSRF KKKCFKLTRK MPIIGRKIQD KLNKTKDDIS KNMSFLKVDK EYVKALPSQG
     LSSSAVLEKL KEYSSMDAFW QEGRASGTVY SGEEKLTELL VKAYGDFAWS NPLHPDIFPG
     LRKIEAEIVR IACSLFNGGP DSCGCVTSGG TESILMACKA YRDLAFEKGI KTPEIVAPQS
     AHAAFNKAAS YFGMKIVRVP LTKMMEVDVR AMRRAISRNT AMLVCSTPQF PHGVIDPVPE
     VAKLAVKYKI PLHVDACLGG FLIVFMEKAG YPLEHPFDFR VKGVTSISAD THKYGYAPKG
     SSLVLYSDKK YRNYQFFVDT DWQGGIYASP TIAGSRPGGI SAACWAALMH FGENGYVEAT
     KQIIKTARFL KSELENIKGI FVFGNPQLSV IALGSRDFDI YRLSNLMTAK GWNLNQLQFP
     PSIHFCITLL HARKRVAIQF LKDIRESVTQ IMKNPKAKTT GMGAIYGMAQ TTVDRNMVAE
     LSSVFLDSLY STDTVTQGSQ MNGSPKPH
//
